Silexion Therapeutics Reports First Quarter 2025 Financial

Results and Provides Business Update

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data

demonstrating efficacy against both primary tumors and metastases in orthotopic models;

strengthened financial position with over $9 million gross funds raised in Q1 2025

GRAND CAYMAN, Cayman Islands, May 13, 2025 - Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on recent business developments.

“The first quarter of 2025 highlighted our continued clinical traction and saw a number of major developments for Silexion, marked by strong preclinical data from our SIL204 program and successful financing activities that strengthened our balance sheet,” said Ilan Hadar, Chairman and CEO of Silexion. “Our latest orthotopic model data demonstrated SIL204’s ability to significantly reduce both primary tumor burden and metastatic spread when administered systemically, representing a potential paradigm shift in treating KRAS-driven cancers. Building on this success, we unveiled our expanded dual-route development strategy for SIL204, positioning us to potentially address both primary tumors and metastases in challenging oncology indications. With our enhanced financial position and strategic collaborations announced in the recent weeks, we believe we are well-positioned to advance our pipeline toward clinical development.”

•

Strengthened Financial Position: During Q1 2025, the Companycompleted a public offering of ordinary shares, pre-funded warrants, and ordinary warrants, raising gross proceeds of approximately $5.0 million. An additional $0.9 million of proceeds was received from the exercise of certain of those warrants. In late January, Silexion completed a warrant exercise inducement transaction, generating additional gross proceeds of approximately $3.3 million. Additionally, in March 2025, the Company entered into an agreement to retire a promissory note in a principal amount of $1.25 million, through a combination of cash payments and share issuances, and completed the retirement of the promissory note on March 18, 2025.

About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company’s first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion’s business strategy, and in particular, its dual-route development strategy for SIL204, business collaboration with Catalent, and plans to initiate further studies and make regulatory submissions as part of its pipeline toward clinical development, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of Silexion’s success in completing preclinical studies and initiating clinical trials; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

 

		March 31,				December 31
		2025				2024
		U.S. dollars in thousands
Assets
CURRENT ASSETS:
Cash and cash equivalents		$	6,152			$	1,187
Restricted cash			34				35
Prepaid expenses			1,478				966
Other current assets			58				62
TOTAL CURRENT ASSETS			7,722				2,250
NON-CURRENT ASSETS:
Restricted cash			47				48
Long-term deposit			5				5
Property and equipment, net			32				30
Operating lease right-of-use asset			502				530
TOTAL NON-CURRENT ASSETS			586				613
TOTAL ASSETS		$	8,308			$	2,863

* Net of 421 treasury shares held by the Company as of March 31, 2025 and December 31, 2024

 

 

 

		Three months ended March 31
		2025				2024
		U.S. dollars in thousands
OPERATING EXPENSES:
Research and development (including $0 and $17 from related parties for the three months period ended March 31, 2025 and 2024, respectively)		$	590			$	961
General and administrative (including $21 and $12 from related parties for the three months period ended March 31, 2025 and 2024, respectively)			1,060				289
TOTAL OPERATING EXPENSES			1,650				1,250
OPERATING LOSS
Financial expenses, net (including $32 and $75 from related parties for the three months period ended March 31, 2025 and 2024, respectively)			85				168
LOSS BEFORE INCOME TAX		$	1,735			$	1,418
INCOME TAX			*				5
NET LOSS		$	1,735			$	1,423
Attributable to:
Equity holders of the Company			1,735				1,373
Non-controlling interests			-				50
		$	1,735			$	1,423
LOSS PER SHARE, BASIC AND DILUTED		$	0.26			$	12.29**
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE			6,779,205				111,726**

* Represents an amount less than $1

For More Financial Information:

For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for the subject periods, please review the Company’s quarterly report on Form 10-Q for the quarter ended  March 31, 2025, available under the Company's EDGAR profile at https://www.sec.gov/edgar

Company Contact

Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Capital Markets & IR Contact
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com

---